Latest Headlines

Latest Headlines

Transgene teams with Jennerex in $116M cancer pact

France's Transgene is hitching its wagon and a $116 million slate of milestones to a new collaboration with San Francisco-based Jennerex on a virus-based cancer cell-killing therapy. In the pact the

Novartis offers $955M deal to snare Transgene drug option

Novartis has put up $10 million and promised up to €700 million more in milestones in exchange for an option on Transgene's promising, late-stage cancer immunotherapy. France's Transgene will

Is Transgene closing in on a major collaboration?

Analysts are eager to see France's Transgene nail down a licensing pact for the promising lung cancer vaccine TG4010. Pierre Corby, an analyst at Aurel BGC, told Bloomberg two weeks ago that he had

Transgene shares up on positive cancer vax data

Shares of France's Transgene jumped about 10 percent on Monday after new data from a Phase IIb trial of TG4010 demonstrated a survival benefit for non-small cell lung cancer patients. The French

Transgene to partner after cancer vax passes trial

France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. The European trial of 148 patients saw progression-free survival of 44 percent of